The Latest Breaking News from FDA

The recalled product was sold at stores in Oregon and Washington

Hims stock skidded Thursday after the FDA determined Eli Lilly's tirzepatide — which sells as a weight-loss drug — is no longer in shortage.

Novo Nordisk A/S is moving closer to adding more sales for its blockbuster GLP-1 drug semaglutide to treat a chronic liver disease.

As faces chase agelessness, cosmetic procedures are surging – and the taboo against commenting on women’s appearances is beginning to dissolve

Altria Group, Inc. (MO) has emerged as a dominant market player, thanks to its diverse tobacco portfolio that’s leading the shift from traditional smoking. With strong financial performance and over 50 years of consistent dividend payouts, could this stable, high-performing stock be a worthy addition to your portfolio? Read on….

We recognize some of the most staggering, game-changing, life-improving developments of the year.

Doctors weigh in on the popular supplement during cold season

“Daniel was probably the best boss I ever had,” said one of his former deputies, “but also one of the most challenging.”

The FDA has issued its strongest safety alert, a boxed warning, on a menopausal drug linked to severe liver injury.